Radziszewski Andrzej, Gajda Mariusz, Pituch-Noworolska Anna, Drozdz Maciej, Kraśniak Andrzej, Kaczmarczyk Ireneusz, Hołyś Stanisława, Zurowski Janusz, Sydor Antoni, Sułowicz Władysław
Department of Nephrology, Jagiellonian University, College of Medicine, Kraków.
Przegl Lek. 2007;64(7-8):470-5.
Hepatitis B is a serious epidemiological problem in uremic patients treated with renal replacement therapy. A high proportion of hemodialyzed patients do not respond to the standard method of intramuscular (i.m.) hepatitis B vaccination. Low-dose intradermal (i.d.) inoculations and supplementary i.m. injections have been reported to improve the responsiveness in formerly non responding uremic patients. We applied a inoculation schedule of 10 microg Engerix B i.d. in 49 pts and i.m. (control group) in 13 pts once a week during 12 consecutive weeks in order to compare the effectiveness of the various ways of immunization in maintenance dialyzed patients not responding to standard vaccination. Serum anti-HBs antibody level, as well as biochemical and immunological parameters were examined. Already one month after initiation of the cycle, 57.1% of patients in the i.d. group responded by achieving the minimum protective anti-HBs antibody level (>10 IU/I.); while 14.3% reached full adequate anti-HBs antibody level (>100 IU/I.). After the full therapy period, anti-HBs antibody level >100 IU/I. was achieved in 42.9% of the patients, while a total of 81.7% of patients reached the anti-HBs antibody level >10 IU/I. In 18.4% of patients no response was observed. Surprisingly similar results were achieved in the i.m. group. Twelve months after termination of the inoculation cycle we noted decrease of anti-HBs antibody level; the values >100 IU/ I. was observed only in 18.4% of the study group, while 87.8% reached a titre >10 IU/I. We found a relationship between the effectiveness of immunization and RBC count, total serum protein and albumin levels and GGTP activity. Mitogen stimulation indexes in both groups were 4-5 times lower in comparison to reference values in the general population. In the study group that did not respond to vaccination, mitogen stimulation indexes were 2 times lower as compared to the group characterized as having a good response. In conclusion, the route of injection seems to be less important than the frequency and number of doses of the vaccine. Anemia and malnutrition may be responsible for the worse response to vaccination against hepatitis B virus.
对于接受肾脏替代治疗的尿毒症患者而言,乙型肝炎是一个严重的流行病学问题。很大一部分接受血液透析的患者对肌内注射(i.m.)乙型肝炎疫苗的标准接种方法无反应。据报道,低剂量皮内注射(i.d.)和补充肌内注射可提高既往无反应的尿毒症患者的反应性。我们对49例患者应用10微克安在时B皮内接种方案,对13例患者应用肌内注射(对照组),连续12周每周一次,以比较在对标准接种无反应的维持性透析患者中不同免疫方式的有效性。检测了血清抗-HBs抗体水平以及生化和免疫参数。在接种周期开始仅1个月后,皮内注射组57.1%的患者通过达到最低保护性抗-HBs抗体水平(>10 IU/I.)产生反应;而14.3%的患者达到完全足够的抗-HBs抗体水平(>100 IU/I.)。在整个治疗期后,42.9%的患者抗-HBs抗体水平>100 IU/I.,而共有81.7%的患者抗-HBs抗体水平>10 IU/I.。18.4%的患者未观察到反应。令人惊讶的是,肌内注射组也取得了类似的结果。接种周期结束12个月后,我们注意到抗-HBs抗体水平下降;仅18.4%的研究组患者观察到抗-HBs抗体水平>100 IU/I.,而87.8%的患者抗体滴度>10 IU/I.。我们发现免疫效果与红细胞计数、总血清蛋白和白蛋白水平以及γ-谷氨酰转肽酶活性之间存在关联。两组的丝裂原刺激指数均比普通人群的参考值低4至5倍。在对疫苗无反应的研究组中,丝裂原刺激指数比反应良好的组低2倍。总之,注射途径似乎不如疫苗的接种频率和剂量重要。贫血和营养不良可能是对乙型肝炎病毒疫苗反应较差的原因。